Market Overview - In November, the A-share market continued the high-level fluctuations from October, with the three major indices all closing down: the Shanghai Composite Index fell by 1.67%, the Shenzhen Component Index decreased by 2.95%, and the ChiNext Index dropped by 4.23% [1] - Despite the overall market decline, 2,303 private equity products reached historical highs in net value in November, representing approximately 44.59% of private equity products established for over a year [1] Private Equity Product Types - Among the private equity products, 1,199 were non-quantitative, while 1,104 were quantitative. The majority were stock strategy products, with 1,362 products accounting for about 59.14% [1] - Other strategies included multi-asset strategy products (321), futures and derivatives strategy products (302), bond strategy products (233), and combination fund products (85) [1] Company Size and Performance - The largest number of products came from private equity firms with assets under 500 million, totaling 778 products (approximately 34%); firms with over 10 billion had 389 products [2] - A detailed analysis of the top 20 performing private equity products by strategy was provided, focusing on those with over 5 billion in assets [2] Long-Standing Products - Among the private equity products that reached historical highs, 20 were established for over 10 years, with 16 classified as "Double Ten Funds," achieving annualized returns exceeding 10% [3] - The majority of these long-standing products were subjective long-only products (12), with macro strategy and CTA products each having 3, and quantitative long-only and FOF funds each having 1 [3] Notable Products and Managers - The largest product by size was the macro strategy product "Kai Feng Macro Strategy No. 9" managed by Shenzhen Kai Feng Investment, established on July 29, 2015, with a scale of approximately *** billion and an annualized return close to ***% [4][6] - The quantitative CTA product "Shuanglong-Longyuan No. 1," managed by Shuanglong Investment, also showed significant performance with a scale of approximately *** billion and an annualized return close to ***% [6] Quantitative Long-Only Products - There were 515 products classified under the "stock-quantitative long-only" strategy among private equity products with over 5 billion in assets [7] - The top 5 performing products in this category were from Jin Tong Investment, Jiu Ming Investment, Han Rong Investment, and others, with the performance threshold for the top 20 being close to ***% [7] Subjective Long-Only Products - A total of 331 products were categorized as "stock-subjective long-only," with only one product from a firm with over 10 billion assets making it to the top 20 [11] - The top 5 products in this category were from Neng Jing Investment Holdings, Shanghai Ge Ru Private Equity, and others [11] Futures and Derivatives Strategy - There were 169 products under the "futures and derivatives strategy," with the top 5 performers coming from Yi Zu Investment, Hai Sheng Fund, and others [15] - The leading product was "Yi Zu Qing Gui Li Dong," managed by Lin Jianwei, with significant returns [18] Multi-Asset Strategy - A total of 207 products were classified under the "multi-asset strategy," with the top 5 performers from Juqi Investment, Hai Sheng Fund, and others [19] - The product "Xi Shi Run Huang Jin Zeng Qiang No. 1 A Class Share," managed by Guan Xin, was noted for its performance [23]

Core Viewpoint - The A-share market experienced a high-level fluctuation in November, continuing the trend from October, with all three major indices declining. The Shanghai Composite Index fell by 1.67%, while the Shenzhen Component and ChiNext Index dropped by 2.95% and 4.23%, respectively. Despite this, 2303 private equity products reached historical highs in net value, representing approximately 44.59% of private equity products established for over a year [2][3]. Summary by Category Private Equity Product Types - Among the private equity products, 1199 were non-quantitative and 1104 were quantitative. The majority were stock strategy products, with 1362 products (about 59.14%), followed by multi-asset strategy products (321), futures and derivatives strategy products (302), bond strategy products (233), and combination fund products (85) [2]. Company Scale - The largest number of products came from private equity firms with assets under management below 500 million, totaling 778 products (34%). There were 389 products from firms with over 10 billion in assets [3]. Long-Established Products - Among the private equity products that reached historical highs, 20 were established for over 10 years, with 16 of them achieving an annualized return exceeding 10%. The majority of these long-established products were subjective long positions (12), with macro strategies and CTA products each accounting for 3 [4]. Top Performing Products - The largest product by scale was "Kai Feng Macro Strategy No. 9" managed by Shenzhen Kai Feng Investment, established on July 29, 2015, with a scale of approximately *** billion and an annualized return close to ***% [6][7]. - The top-performing quantitative long products included 515 products, with the highest returns coming from firms like Jin Tong Investment and Jiu Ming Investment [8][9]. - In the subjective long strategy category, 331 products reached historical highs, with top performers from companies like Neng Jing Investment and Qian Tu Investment [11][15]. Futures and Derivatives Strategy - There were 169 products under the futures and derivatives strategy, with the top product being "Yi Zu Qing Gui Li Dong" managed by Yi Zu Investment, achieving significant returns [16][19]. Multi-Asset Strategy - A total of 207 products were categorized under multi-asset strategies, with the top product being "Xi Shi Run Gold Enhanced No. 1A" managed by Xi Shi Run Investment, which also achieved notable returns [20][23].

Core Insights - The average return of private equity fund managers in the past year reached 21.84%, significantly outperforming the market [2] - Stock fund managers showed the highest average return of 25.52%, benefiting from the recovery of the A-share market since "924" [2][4] - Fund managers with assets under management between 0-5 billion yuan had the best performance, with average returns of 23.38% [2][4] By Strategy - Stock Strategy: 1471 managers, 2853 products, total AUM of 2330.34 billion yuan, average return of 25.52% [4] - Futures and Derivatives: 393 managers, 652 products, total AUM of 393.50 billion yuan, average return of 17.27% [4] - Multi-Asset: 297 managers, 531 products, total AUM of 476.29 billion yuan, average return of 19.32% [4] - Bond: 179 managers, 409 products, total AUM of 445.17 billion yuan, average return of 9.70% [4] - Combination Funds: 63 managers, 94 products, total AUM of 42.59 billion yuan, average return of 24.17% [4] By Company Size - Managers with over 10 billion yuan AUM: 114 managers, 586 products, total AUM of 998.51 billion yuan, average return of 20.66% [4] - Managers with 5-10 billion yuan AUM: 400 managers, 707 products, total AUM of 468.51 billion yuan, average return of 23.38% [4] - Managers with 0-5 billion yuan AUM: 1442 managers, 2104 products, total AUM of 750.51 billion yuan, average return of 22.52% [4] Top Performers - Wang Chen from Jiukun Investment topped the list among managers with over 10 billion yuan AUM [5][9] - Wu Xing from Shenzhen Kaifeng Investment led the 50-100 billion yuan category [10][11] - Chen Yu from Shennong Investment ranked first among 20-50 billion yuan managers, focusing on innovative drugs [15][19] - Sun Jie from Nengjing Investment led the 10-20 billion yuan category [22][23] - Hu Shiyuan from Wantao Private Equity topped the 5-10 billion yuan category [29][30] - Tan Guanhua from Hainan Xiangyuan Private Equity led the 0-5 billion yuan category [30][32]